Bridging the gap: Facilitating linkage to care for persons identified with chronic hepatitis C infections through a public health program
AASLD LiverLearning®, Arlene Sena, 144648
Effect of interferon free antiviral treatment on lipid metabolism, lipid oxidation and insulin-resistance in chronic hepatitis C patients with advanced liver disease
AASLD LiverLearning®, elisa biliotti, 144905
Effect of pre-existing Hepatitis C NS3 Q80K variant in Genotype 1a and NS5A Y93H variant in Genotype 3 for interferon-free treatment combinations with direct antiviral agents (DAAs): Real-life experience from a multicenter study in Sweden and Norway
AASLD LiverLearning®, Johan Lennerstrand, 144906
Transient Elastography in Assessment of Liver Fibrosis in Children with Chronic Hepatitis B: PEG-B-ACTIVE Liver Elasticity Substudy
AASLD LiverLearning®, Vedran Pavlovic, 144664
Increase in 10-Year Framingham Cardiovascular Risk Following HCV Eradication with DAA-Based Therapy in HIV/HCV-Coinfected Patients
AASLD LiverLearning®, Teresa Aldámiz-Echevarría, 144921
Ledipasvir/Sofosbuvir for 8 Weeks Results in High SVR Rates in Treatment-Naïve Patients with Chronic HCV Infection and HIV/HCV Co-Infection
AASLD LiverLearning®, Vasily Isakov, 144922
Progression of initially mild hepatic fibrosis in Chronic hepatitis B patients: a prospective repeat liver biopsy study
AASLD LiverLearning®, Xiao ling Chi, 144680
Does the presence of cirrhosis influence on the mortality rate in patients with acute on chronic liver failure?
AASLD LiverLearning®, Sombat Treeprasertsuk, 144937
Long-term prognosis of patients who survived from acute-on-chronic liver failure based on KACLiF cohort
AASLD LiverLearning®, Eileen Yoon, 144938
Hepatitis B surface antigen (HBsAg) seroclearance, hepatocellular carcinoma (HCC) and liver-related death (LRD) risk among Alaska Native (AN) persons with indeterminate phase chronic hepatitis B virus infection (CHB) — Alaska, 2001-2014
AASLD LiverLearning®, Michael Bruce, 144696
Monocyte HLA-DR expression, neutrophil oxidative burst capacity and cytokine analysis in patients with decompensated cirrhosis with and without acute-on-chronic liver failure (ACLF).
AASLD LiverLearning®, Ajay Duseja, 144953
MELD-Na and SBP predict mortality in Refractory Ascites
AASLD LiverLearning®, Sanaa Ayyoub, 144954
Male and hepatitis B infection are independent factors affecting patient’s compliance with surveillance of hepatocellular carcinoma
AASLD LiverLearning®, Satoshi Oeda, 144713
Patients with Refractory Ascites Treated with alfapump® System (AP) have Better Health-related Quality of Life (HRQL) as Compared to those Treated with Large Volume Paracentesis (LVP): Results of a Multicenter Randomized Controlled Study
AASLD LiverLearning®, Zobair Younossi, 144969
The Burden of Hepatorenal Syndrome among Commercially-Insured and Medicare Patients in the United States
AASLD LiverLearning®, Khurram Jamil, 144970
Expression profile alterations of lncRNAs on the molecular pathogenesis of hepatitis B*
AASLD LiverLearning®, Sunde Yilmaz Susluer, 144729
Rifaximin has no effect on hemodynamics in decompensated cirrhosis - A randomized, double blind, placebo controlled trial
AASLD LiverLearning®, Nina Kimer, 144985
Rifaximin has limited effect on the inflammatory state and bacterial translocation in the patient with stable decompensated cirrhosis. Results from a randomized, placebo controlled trial.
AASLD LiverLearning®, Nina Kimer, 144986
Low serum HBsAg level predicts HBsAg seroclearance and sustained response in chronic hepatitis B after stopping oral NUCs
AASLD LiverLearning®, Apinya Leerapun, 144745
The Multikinase-Inhibitor Regorafenib Improves Portal Hypertension In Presence And Absence Of Cirrhosis In Rats
AASLD LiverLearning®, Uschner Frank Erhard, 145001
Antioxidant attenuates hyperdynamic circulation by mitigating mesenteric inflammation and nitric oxide production in cirrhotic rats
AASLD LiverLearning®, hongqun liu, 145002
Optimization of a Phase 2 Study Design in Chronic Hepatitis B (CHB) Patients Based on Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) from Phase 1 Studies Using Two Prodrugs of a Toll-like Receptor 7 (TLR7) Agonist
AASLD LiverLearning®, Joseph Grippo, 144761
Pharmacokinetics, Safety and Antiviral Activity of CMX157, a Novel Prodrug of Tenofovir, Administered as Ascending Multiple Doses to Healthy Volunteers and HBV-Infected Subjects
AASLD LiverLearning®, John Sullivan-Bolyai, 144778
Limited Real-World Provider Prescription of 8 week LDV/SOF Regimen: A potential barrier in widespread treatment access
AASLD LiverLearning®, Chloe Gross, 144536
Baseline Quantitative Hepatitis B Core Antibody Level strongly Predicts 240-week Treatment Response in HBeAg-positive Chronic Hepatitis B Patients Receiving Entecavir
AASLD LiverLearning®, Jinghang Xu, 144794
JKB-122 is Effective, Alone or in Combination with Prednisolone in Con A-induced Hepatitis, a Model for Autoimmune Hepatitis.
AASLD LiverLearning®, Mei-Chi HSU, 144552
Metabolic syndrome, hepatic steatosis and genotype 1b C virus compensated liver cirrhosis in the era of Direct Acting Antiviral therapy
AASLD LiverLearning®, Catalina Mihai, 144810
A novel murine model to deplete HSCs from normal liver with GFP-specific CD8+ T cells
AASLD LiverLearning®, Takuma Tsuchida, 144568
Genotype 3 Infection In DAA Era: Preliminary Reports Of a Real Life Northern Italy Network For Viral Hepatitis
AASLD LiverLearning®, pasulo luisa, 144826
Loss of retinaldehyde dehydrogenase 1 enzymatic function attenuates liver fibrosis in a murine model of cirrhosis
AASLD LiverLearning®, Loretta Jophlin, 144584
Glyco-isomer of serum Mac-2-binding protein (M2BPGi) were dramatically decreased due to anti-viral therapy in chronic hepatitis C (CHC) patients
AASLD LiverLearning®, Mina Hamano, 144842
Management Of Refractory Variceal Bleed With Dannis-Ella Stent In Patients With Acute On Chronic Liver Failure
AASLD LiverLearning®, RAKHI MAIWALL, 144600
Treatment of Chronic Hepatitis C Genotype 4 -infected Patients with Ombitasvir/Paritaprevir/Ritonavir Plus Ribavirin: Real Life Data From Saudi Arabia
AASLD LiverLearning®, khalid alswat, 144857
Ombitasvir, Paritaprevir, Ritonavir, Dasabuvir and Ribavirin Pharmacokinetics in HCV-Infected Subjects with Chronic Kidney Disease Stage 4 (Severe Renal Impairment) or Stage 5 (End-Stage Renal Disease)
AASLD LiverLearning®, Diana Shuster, 144858
Ledipasvir/Sofosbuvir (LDV/SOF) treatment of naïve patients with mild chronic hepatitis C (CHC) genotype 1 (GT1) compared to patients with significant fibrosis: is it a cost-effective therapy?
AASLD LiverLearning®, Maria Buti, 144616
Safety and efficacy of regimens including direct acting antivirals (DAAs) in chronic hepatitis C (CHC) patients over the age of 70 years
AASLD LiverLearning®, Emmanouil Sinakos, 144873
Effectiveness of hcv antiviral treatment in patients with cirrhosis or advanced fibrosis and end-stage kidney disease on dialysis
AASLD LiverLearning®, Francesca Romana Ponziani, 144874
Outpatient primary care physician utilization before and after index hospitalization in patients with decompensated liver cirrhosis enrolled in a large national health insurance administrative database
AASLD LiverLearning®, Steven Scaglione, 144632
Primary care based model using patient navigators highly successful in obtaining HCV medications for inner-city HCV-monoinfected patients
AASLD LiverLearning®, Wilma Toribio, 144889
chronic hepatitis c treatment with new generation direct-acting antivirals - real-life data from a portuguese center
AASLD LiverLearning®, LURDES SANTOS, 144890
Module 1: Anatomy and Physiology of the Liver
AASLD LiverLearning®, Tamar Taddei, 119131
Management of Hepatic Encephalopathy
AASLD LiverLearning®, Jasmohan Bajaj, 154717
Surgery Risk Assessment in the Cirrhotic Patient
AASLD LiverLearning®, Patrick Northup, 154716
Update in Wilson Disease
AASLD LiverLearning®, Eve Roberts, 154715
Pegylated interferon alfa-2a (40KD) is efficacious and safe in treatment of HBeAg-positive children with chronic hepatitis B: Peg-B-Active study
AASLD LiverLearning®, Stefan Wirth, 155355
Hepatology Associates Course
AASLD LiverLearning®, Session Speakers, 155769
HIV, HBV, HCV Coinfections
AASLD LiverLearning®, Douglas Dieterich, 154676
Approach to the Patient with Iron Overload
AASLD LiverLearning®, Kris Kowdley, 154675
Adult Living Donor Liver Transplant: Donor and Recipient Considerations
AASLD LiverLearning®, Rebecca Duke, 154674
Awarded Poster Presentation
AASLD LiverLearning®, Anna Hefner, 154673
iPSC and Disease Modeling in the Liver
AASLD LiverLearning®, Ludovic Vallier, 154691
The Impact of Cirrhotic PVT on Liver Transplant: A Medical Perspective
AASLD LiverLearning®, Nicolas Intagliata, 154701
Complications of Cholestatic Liver Diseases
AASLD LiverLearning®, Cynthia Levy, 154672
iPSCs and Correction of A1AT Deficiency
AASLD LiverLearning®, Andrew Wilson, 154690
Cholangiocytes From iPSC
AASLD LiverLearning®, Romina Fiorotto, 155708
Treatment of PVT in Cirrhosis: Who, When and How
AASLD LiverLearning®, Juan Carlos Garcia-Pagan, 154700
Etiology of Liver Disease: Does it Make a Clinical Difference?
AASLD LiverLearning®, Jordi Bruix, 154712
Hepatocytes From iPSC
AASLD LiverLearning®, Holger Willenbring, 154688
Diagnosis and Natural History of PVT In Cirrhosis
AASLD LiverLearning®, Dominique Valla, 154699
Statins and Metformin as Chemoprevention for HCC
AASLD LiverLearning®, Lewis Roberts, 154711
Panel Discussion
AASLD LiverLearning®, Session Speakers, 155768
Future Landscape With HCV Therapy
AASLD LiverLearning®, Fred Poordad, 154669
Session II: Epidemiology and Clinical Insights
AASLD LiverLearning®, Gregory Gores, 154709
Liver Transplantation for NASH Associated HCC
AASLD LiverLearning®, Kimberly Ann Brown, 154710
Cirrhosis – Beyond Portal Hypertension
AASLD LiverLearning®, Lucy Mathew, 154668
Engineering of the Liver via iPSC
AASLD LiverLearning®, Takanori Takebe, 154685
Does Prophylactic Anticoagulation Alter the Course of Cirrhosis? Lessons from Prophylactic Trials
AASLD LiverLearning®, ERICA VILLA, 154698
Natural History: The Magnitude of the Problem from Hepatology Clinic Perspective
AASLD LiverLearning®, Augusto Villanueva, 154708
Parenchymal Extinction in 2016: What is the Human Evidence?
AASLD LiverLearning®, Ian R. Wanless, 154697
Management of Metabolic Syndrome and NASH
AASLD LiverLearning®, Rohit Loomba, 154667
Induced Pluripotent Stem Cells in the Future of Gastroenterology/Hepatology
AASLD LiverLearning®, Stephen Duncan, 154684
Diabetes Associated HCC: The Molecular Profile
AASLD LiverLearning®, Jessica Zucman-Rossi, 154707
Coagulation, Thrombin, Fibrosis and Inflammatory Pathways in the Liver
AASLD LiverLearning®, James Luyendyk, 154696
NAFLD Promotes HCC by Causing CD4(+)T Cell Depletion
AASLD LiverLearning®, Tim Greten, 154706
Developmental Biology: The Foundation for Gastrointestinal Tissue Engineering
AASLD LiverLearning®, James Wells, 154681
Hepatology Associates Course: Session I
AASLD LiverLearning®, Lisa Richards, 154664
Managing Alcoholic Hepatitis
AASLD LiverLearning®, Vijay Shah, 154666
Cirrhosis as a Prothrombotic State: Overview and Update
AASLD LiverLearning®, Ton Lisman, 154695
FGF19 immunostaining as biomarker for trial enrichment testing FGFR4 inhibitors in HCC
AASLD LiverLearning®, Agrin Moeini, 144134
Baseline Immune Changes following DAA Therapy may Predict Early Viral Clearance
AASLD LiverLearning®, Lisa Barrett, 144391
Hyperlipidemia and Non-Alcoholic Steatohepatitis are Risk Factors for Hepatocellular Carcinoma Development in the Absence of Cirrhosis
AASLD LiverLearning®, Jennifer Phan, 144150
A Human In Vitro Surrogate System For Studying Non-Alcoholic Steatohepatitis (NASH)
AASLD LiverLearning®, Ryan Feaver, 144407
Biological significance of a disintegrin and metalloproteinase 21 expression in hepatocellular carcinoma
AASLD LiverLearning®, Masaaki Takamura, 144166
Simultaneous recruitment of Th17 cells in hepatic tissue and in intra-abdominal visceral fat of NASH patients undergoing bariatric surgery
AASLD LiverLearning®, Monika Rau, 144423
Impact of age and race/ethnicity for women with gastrointestinal and hepatobiliary malignancies in the U.S.
AASLD LiverLearning®, Vicky Bhagat, 144182
The role of cytochrome P450-2E1 in fast food-induced hepatic fibrosis
AASLD LiverLearning®, Mohamed Abdelmegeed, 144439
Stereotactic body radiation therapy combined with transcatheter arterial chemoembolization for small hepatocellular carcinoma.
AASLD LiverLearning®, Tomokazu Kawaoka, 144198
Intrahepatic Cholangiocarcinoma Presenting as LI-RADS 5 'HCC'
AASLD LiverLearning®, Raja Koteswar Dhanekula, 144214
Impact of screening on survival in Hepatocellular Carcinoma patients with Chronic Hepatitis B - A regional U.S. population based study
AASLD LiverLearning®, Rasham Mittal, 144230
Regional differences in admissions and treatment outcomes for patients with hepatocellular carcinoma (HCC) in Thailand: data from the national universal health care
AASLD LiverLearning®, Ml.Taya Kitiyakara, 144246
PNPLA3 (rs738409 C>G) contributes to low viral load and decreased risk of hepatocellular carcinoma in HCV genotype 1b cirrhotic patients.
AASLD LiverLearning®, Sona Frankova, 144262
Outcomes of Liver Transplant from Elderly Deceased Donors in the United States
AASLD LiverLearning®, Mica Esquenazi, 144278
The Numbers of New Waitlist Registrants and Removals are Outpacing the Number of Liver Transplants: National Trends and Regional Variation from 2003 through 2014
AASLD LiverLearning®, Eric Orman, 144294
Real World Predictors of Hospital Readmission for Hepatic Encephalopathy after Placement of Transjugular Intrahepatic Portosystemic Shunt
AASLD LiverLearning®, Michael Rowley, 144310
Good glycemic control contributes to an improvement in hyperammonemia by occlusion of portosystemic shunts in cirrhotic patients with diabetes
AASLD LiverLearning®, Tsuyoshi Ishikawa, 144326
LDV/SOF combination is associated with 100% SVR in patients with thalassemia major: a preliminary report from an Italian multicenter study
AASLD LiverLearning®, Alessandra Mangia, 144342
Prediction And Impact Of Alcohol Abstinence After An Episode Of Alcoholic Hepatitis: A Long-Term Follow-Up Study
AASLD LiverLearning®, Jose Altamirano, 144102
Rapid intrahepatic and peripheral blood HCV RNA decline and HCV-specific immune response increase during IFN-free DAA therapy in HCV treatment-naïve patients
AASLD LiverLearning®, Sonya MacParland, 144358
Establishment of a cellular model to study ethanol-induced lipophagy
AASLD LiverLearning®, Xiao-Ming Yin, 144118
Vitamin D antagonizes the expression of genes that are epigenetically regulated by Hepatitis C virus
AASLD LiverLearning®, Ran Tur-Kaspa, 144374